AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06613191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
Description: Participant will be taking either P2Y12 inhibitor at time of colonoscopy
Study NCT06473207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischemic post conditioning sessions
Description: Three sessions of RIPOST (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest), as follows: four cycles of cuff inflation to 200 mmHg for 5 min and then deflation to 0 mmHg for another 5 min (40 min total duration of the intervention), using an inflatable thigh tourniquet
Study NCT06473207 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham sessions
Description: Three sessions of a sham procedure (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest), as follows : application of a thigh tourniquet during 40 min without any inflation
Study NCT06434441 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone augmentation
Description: Maxillary alveolar bone reconstruction
Study NCT06612450 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: turbinate surgery
Description: Turbinoplasty to decrease the turbinate size in cases with turbinate hypertrophy with mainly soft tissue component without sacrificing the mucosal function
Study NCT06611943 — intervention group
Intervention type: BEHAVIORAL
Intervention: DietCoach
Description: Participants are invited to give at least one dietary recommendation to a patient\&#39;s food purchase data using the DietCoach platform.
Study NCT06612411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B. subtilis
Description: 2 capsules, 3 times a day, orally taken for one month
Study NCT06612411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dead B. subtilis
Description: 2 capsules, 3 times a day, orally taken for one month
Study NCT06612398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative preparation video
Description: An animated video illustrating the story of a child's journey through the hospital facilities, including the anaesthesia induction, and the postoperative return home.
Study NCT06612619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dyad instruction
Description: Rather than being instructed solo or one-on-one the trainees are instructed in pairs of two (dyad).
Study NCT06612359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BOOST GAIT Program
Description: In addition to usual care, participants will undergo additional therapy over a four-week period, with sessions occurring five times per week for one hour. The BOOST GAIT sessions will be conducted as group-based therapy with four patients and two physiotherapists present to oversee the performance of mobility-specific exercises, including sit-to-stand transfers, standing and stepping, and eventually walking.
Study NCT04658693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implanted Multi contact stimulating electrode and intramuscular electromyography recording electrode
Description: See arm description
Study NCT05877586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CLARE app
Description: CLARE will contain materials on hospital discharge preparation, Covid care, and caregiver self-care, all of which have already been vetted by the DUHS Patient and Family Education department. Existing CLARE teaching on Covid covers isolation; quarantine; home sanitization; and monitoring for Covid symptoms such as cough, fever, fatigue, and shortness of breath. All will be reviewed and amended to reflect the latest CDC guidelines for Covid care at the time of pilot implementation. CLARE will also include reminders on examining the After-Visit-Summary to determine home medications and information on follow-up care.~CLARE will have two sessions of training and support to caregivers that can be delivered before hospital discharge and daily for seven days after discharge.
Study NCT05224661 — intervention group
Intervention type: OTHER
Intervention: Prospective determination of the clinical utility of measurable residual disease (MRD) testing
Description: Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).
Study NCT05995353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous (IV) Infusion
Study NCT05995353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection
Study NCT04721197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg vouchers
Description: 30-day egg vouchers will be provided monthly, in addition to standard of care.
Study NCT04721197 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will continue to receive the standard of care. No egg vouchers.
Study NCT04721197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants will continue to receive the standard of care. No egg vouchers.
Study NCT05449444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib 4.5 mg/kg/day
Description: Masitinib 4.5 mg/kg/day
Study NCT05449444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT05449444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, sodium cromoglicate, antidepressants, antileukotrienes, proton pump inhibitors, and corticosteroids.
Study NCT05449444 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best supportive care
Description: Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, sodium cromoglicate, antidepressants, antileukotrienes, proton pump inhibitors, and corticosteroids.
Study NCT05449444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib 6.0 mg/kg/day
Description: Masitinib 6.0 mg/kg/day
Study NCT03734523 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Flourish Vaginal Care System
Description: This is not technically an intervention. All women who enroll in the study will be those who have opted to use the Flourish Vaginal Care System. This system is comprised of a vaginal wash (Balance), an intravaginal moisturizing gel (Restore), and a vaginal probiotic supplement (BiopHresh). Balance will be used daily. Restore will be used every other day. BiopHresh will be used twice a week with Restore. All products will be started after the first visit and continue throughout the 6-month study.
Study NCT05897372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib
Description: Standard of care for diabetic kidney disease.
Study NCT05897372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib
Description: Standard of care for diabetic kidney disease.
Study NCT05076877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib tablets will be administered orally, alone or in combination with probe substrates.
Study NCT05076877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam (cytochrome P450 3A4 \[CYP3A4\] substrate) will be administered orally as a syrup as a part of probe substrates.
Study NCT05076877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin (breast cancer resistant protein \[BCRP\] substrate) tablet will be administered orally as a part of probe substrates.
Study NCT05076877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin (organic cation transporter 1 \[OCT1\] substrate) will be administered orally as a syrup as a part of probe substrates.
Study NCT05705921 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy standard
Description: Standard moderately hypofractionated radiotherapy in prostate cancer
Study NCT05705921 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy Hypo-FLAME
Description: Ultra-hypofractionated focal lesion ablative microboost in prostate cancer
Study NCT06306638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection
Study NCT06306638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06306638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Ultrasound Bronchoscopy
Description: Undergo EBUS
Study NCT06361888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine
Description: Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine~1. Surufatinib: 250mg or 200mg, qd~2. Camrelizumab: 200mg, IV drip, Q3W, D1~3. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~4. Gemcitabine : 1000 mg/m2, IV drip, D1, D8
Study NCT06361888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel Plus Gemcitabine
Description: Drug: Nab-paclitaxel Plus Gemcitabine~1. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~2. Gemcitabine : 1000 mg/m2, IV drip, D1, D8
Study NCT04663126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc-99m tilmanocept
Description: IV 250 µg Tilmanocept, labelled with 370 MBq of Tc-99m
Study NCT06306638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interstitial Photodynamic Therapy
Description: Undergo I-PDT
Study NCT06306638 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy
Description: Undergo palliative radiation therapy
Study NCT05273619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8, film-coated tablets, 10 mg
Description: 80 mg/day: 4 tablets (40 mg) twice a day
Study NCT05273619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 tablets twice a day
Study NCT06361888 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Surufatinib with Nab-paclitaxel, and Gemcitabine
Description: Drug: Surufatinib with Nab-paclitaxel, and Gemcitabine~1. Surufatinib: 250mg or 200mg, qd~2. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~3. Gemcitabine : 1000 mg/m2, IV drip, D1, D8
Study NCT05339009 — intervention group
Intervention type: BIOLOGICAL
Intervention: BioADM determination in plasma
Description: BioADM determination in plasma
Study NCT06124196 — intervention group
Intervention type: DEVICE
Intervention: wearable technology
Description: Three wearable devices
Study NCT05524649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food Supplement 1
Description: Probiotic single strain formulation containing Bifidobacterium longum CECT7894 for 3 months 5 drops/day
Study NCT05524649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food Supplement 2
Description: Probiotic single strain formulation containing Pediococcus pentosaceus CECT8330 for 3 months 5 drops/day
Study NCT05524649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 drops/day for 3 months of sunflower oil
Study NCT04703010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography-Near infrared spectroscopy
Description: Brain activity will be measured using 128-channel EEG and 2 channel NIRS during tactile stimulation (15 minutes sequence of vibrations) while the newborn is asleep.
Study NCT04703010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: Structural (T1-T2), siffusion tensor imaging and blood-oxygen level dependant signal will be acquired in a subset of 40 subjects (20 minutes while asleep)
Study NCT04703010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychometric testing
Description: Cognitive evaluation at age 2 (Parental questionnaires on sensory profiles, executive functions and neurodevelopmental disorders screening, child tests : movement assessment battery, Laby, Head-toes-shoulders-knees)
Study NCT05077553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TCI999 probiotic sachet
Description: Testing product
Study NCT05077553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sachet
Description: Blank
Study NCT06257953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Erector spinae plane block will be applied to the patients under real-time ultrasound guidance.
Study NCT06306638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Ancillary studies
Study NCT06306638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06306638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: Given IV
Study NCT06306638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser: ML7710-PDT
Description: Delivering the therapeutic 689+/-3 nm laser light during I-PDT. Measuring light transmission.
Study NCT05241821 — intervention group
Intervention type: PROCEDURE
Intervention: Mechanical thrombectomy
Description: Percutaneous intervention aimed to retrieve/treat clot affecting the cerebral circulation.
Study NCT05241821 — intervention group
Intervention type: DRUG
Intervention: Thrombolytic Agent
Description: Drug aimed to dissolve thrombus affecting the cerebral circulation
Study NCT05559268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 60 MG/ML Injectable Solution [Prolia]
Description: 1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after TKA
Study NCT05559268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 ml (60 mg) subcutaneous injection Saline give in the posterior part of the upper arm after TKA
Study NCT05593653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: 20mg taken at bedtime for 4 weeks
Study NCT05593653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo taken at bedtime for 4 weeks
Study NCT05524766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-785-7 Treatment
Description: Treatment with BTL-785F device (BTL-785-7 applicator) for improvement of overall facial appearance and muscle tone in patients injected with botulinum toxin.
Study NCT05505383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: People with multiple sclerosis will be received a supervised physiotherapy and rehabilitation program.
Study NCT05505383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: People with multiple sclerosis will be received a supervised physiotherapy and rehabilitation program.
Study NCT04820296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solution-Oriented Approach
Description: First Session: Sharing thoughts about perception of childbirth, Creating positive goals, Informing about Birth, Birth Process, Basic Breathing Exercises and Deep Relaxation Exercises, Homework Second Session: Evaluating homework, Sharing thoughts about fear of childbirth, Miracle Question Technique, Evaluating with the Rating Questions Technique, Reframing the problem, Briefing on 'Body-Mind Connection at Birth, Fear-Tension-Pain Cycle, Hormones of Birth' and Breathing exercises, Homework Third session: Evaluating homework, Sharing thoughts about positive birth story, Information on symptoms indicating that the childbirth is approaching, pushing techniques, delivery positions, endorphin massage and breathing exercises (4/8 breaths, full breath when baby moves), Homework Fourth Session: Evaluating homework, Mother Baby Friendly Caesarean and Breathing exercises (3 candles a feather breath), Sharing feelings about the counseling process
Study NCT05376761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The loading dose of DEX (0.5 µg/kg) is transfused intravenously within 15min.The maintaining concentration of DEX, which is started at 0.3 µg/kg/h in the first patient, is determined by the NRMS in the MER signal of the previous patient according to the up and down sequence. If the NRMS is higher than 2.0, a positive response is defined and the concentration of DEX will be added by 0.05µg/kg/h in the next patient. A negative response is defined as NRMS lower than 2.0, and in such cases the concentration of DEX is reduced by 0.3 µg/kg/h.
Study NCT05116371 — intervention group
Intervention type: DRUG
Intervention: 150 mcg levonorgestrel/30 mcg ethinyl estradiol
Description: concurrent use of COC with Nexplanon
Study NCT04826484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel 133 miligrams per 10 milliliter injection
Description: Local wound infiltration with Exparel 133 miligrams per 10 milliliter injection
Study NCT04826484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Local wound infiltration with 0.25% bupivacaine.
Study NCT04826484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Local wound infiltration with 0.25% bupivacaine.
Study NCT06443463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-7000
Description: BHV-7000 50 mg. Participants will take open-label investigational product (IP) once daily
Study NCT06443463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-7000
Description: BHV-7000 75 mg. Participants will take open-label investigational product (IP) once daily
Study NCT06573567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioimpedance
Description: Experimental: use overhydration value obtained by bioimpedance analysis to guide fluid management; the measurements will be obtained once per month
Study NCT06573567 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo Comparator: the measurements will also be obtained once per month, but not revealed to the participants and the care providers
Study NCT06573554 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Contact Cast
Description: Knee High Fiber Glass Total contact Cast
Study NCT06573554 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Slab
Description: Posterior Slab Knee high non walking
Study NCT05946213 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT05946213 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT06650579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given abiraterone acetate
Study NCT06650579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO
Study NCT06650579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06650579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography Angiography
Description: Undergo CCTA
Study NCT06650579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Given IM or SC
Study NCT06650579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given prednisone
Study NCT06650579 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo standard of care radiation therapy
Study NCT06650579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Given PO
Study NCT05556460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DragonFly-T Transcatheter Tricuspid Valve Repair System
Description: To conduct edge-to-edge repair with DragonFly-T System under the guidance of transesophageal echocardiography.
Study NCT05556460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy
Description: Subjects will continue to be managed on medical therapy, per physician discretion
Study NCT05074524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Active rTMS treatment will be delivered at 10 Hz, 100% resting motor threshold, 2000 pulses delivered in five seconds per train with 10-second intra-train pause, delivered once daily five days per week, Monday through Friday for 10 days (10 total treatments). This protocol is adapted from Shen and colleagues (2016), who did not report any adverse events. Liu and colleagues (2020) also used the same protocol and only reported mild side effects of dizziness, headache, and insomnia, which resolved by the 30-day follow-up. However, it is unclear whether these side effects resolved sooner than the 30-day follow-up.